Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory
What is the effect of a new drug Pembrolizumab in combination with chemotherapy, for
Relapsed/Refractory Hodgkin Lymphoma.
Basic Study Information
Purpose:Location: University of Rochester Medical Center
The purpose of this research study is to evaluate a new drug Pembrolizumab in combination
with chemotherapy, for Relapsed/Refractory Hodgkin Lymphoma. The chemotherapy regimen
is called "ICE" and includes three drugs: ifosfamide, carboplatin, and etoposide.
Pembrolizumab is currently Food and Drug Administration (FDA) approved for the treatment
of some patients with melanoma, lung cancer and head and neck cancer, but has not
yet been approved for the treatment of Relapsed/Refractory Hodgkin Lymphoma. The 'ICE'
regimen of chemotherapy is currently FDA approved for the treatment of Relapsed/Refractory
Hodgkin Lymphoma, but has not yet been investigated in combination with pembrolizumab
for this disease. For patients who have a relapse of their Hodgkin's lymphoma, retreatment
with chemotherapy followed by a stem cell transplant is recommended. We know that
obtaining a complete remission (not able to detect any disease on scans) is very important
prior to proceeding to the stem cell transplant. Patients with negative scans have
a lower chance of the disease coming back and a higher chance of achieving a long-term
Study Reference #: UBMT17088-
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Yelena Lerman
Phone: (585) 276-8333
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search